thought call
deliv respect despit base busi eros
increment updat program updat
kra inhibitor main focu call given implic
drug saw investor interest
stock continu sensit news flow updat call
reveal potenti registr enabl monotherapi
begin year along report tumor respons seen colorect
appendic patient lung updat iaslc septemb
remaind could see continu sentiment driven
upsid drug catalyst base busi
continu erod despit better expect enbrel sale driven price
inventori still believ much expect eros gener well
appreci consensu expect exclud sensipar lesser
extent neulasta impact generic/ biosimilar competit
short term expect increment updat biosimilar novel
oncolog even beyond could help support stock despit revenu
growth concern enbrel ip overhang posit amgen
pipelin believ greater clariti pend litig sandoz could
help long-term focus investor becom comfort
reiter outperform tp
valuat risk valu share use sum-of-the-part sotp
dcf analysi assum wacc tvgr result tp
unchang increas ep estim
base
share buyback risk
clinical/development pipelin product fail regulatori fda/ema
approv product commerci market product sell well
predict price inabl achiev price assumpt market risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biotechnolog compani engag
discoveri develop manufactur market human
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum tvgr better
current assumpt base-busi greater
current forecast assum greater expect
growth biosimilar franchis slower expect
declin base busi also assum posit data
readout pipelin asset regulatori
approv abp abp abp
lower base busi sale poorer growth profil
biosimilar busi key pipelin asset assum
slower expect growth biosimilar franchis
regulatori headwind drug approv ip litig
scenario assum lose patent litig soliri
enbrel also assum neg data readout pipelin asset
 close
pipelin updat kra inhibitor expect updat
nsclc iaslc world confer lung cancer septemb barcelona
also report see tumor respons colorect appendic patient
although yet see actual data furthermor enrol complet
monotherapi arm dose expans studi compani enrol patient pd-
combin arm dose expans studi final plan initi
potenti registr enabl monotherapi studi
move biosimilar fda set pdufa date abp infliximab
biosimilar recal recent launch biosimilar herceptin avastin
us see note oncolog franchis expect updat data
anti-bcma bite hle bite compani said could
possibl see updat anti-psma hle bite even plan
request re-examin chmp neg opinion
model adjust lower expect sensipar/mimpara
given lower-than-expect sale gener competit
guid lower sale scenario sensipar vs biosimilar
franchis revenu project increas rais po mvasi
increas revenu enbrel prolia
repatha given resili base busi expect asset
fair significantli wors consensu expect increas cog expect
higher associ cost product biolog slightli rais tax rate
in-lin guidanc result tax expens given
repurchas share lower share count estim
fulli dilut share result dilut ep
figur
figur amgen quarterli annual ep usd
valuat use wacc termin valu growth rate project
fulli dilut share experienc commerci
regulatori organ support diversifi portfolio product domest
intern market believ broad portfolio track record
execut lower risk achiev forecast incorpor view
sotp analysi base sotp dcf primarili driven valuat sale
base busi valu biosimilar aimovig
tezepelumab even valu revenu
combin combin unalloc corpor expens net
debt sotp dcf valu figur
charl martineau pm univers toronto compani mention price
